Igor P. Bilinsky

Biography

Dr. Bilinsky has served as COO since January 2017. Prior to joining AmpliPhi, Dr. Bilinsky was General Manager, Immuno-Oncology and Senior Vice President, Special Operations and Research Operations at Ignyta, Inc., a biotechnology company focused on oncology precision medicines. Prior to Ignyta, he was Senior Vice President, Corporate Development at Vical, Inc., a biotechnology company developing vaccines and immunotherapies for the treatment of cancer and infectious diseases, and Vice President, Business Development and Special Operations at Halozyme Therapeutics. Dr. Bilinsky was also previously Chief Executive Officer of Androclus Therapeutics, a privately-held biotechnology company developing therapeutics for autoimmune and inflammatory diseases, which he originally joined as COO. Dr. Bilinsky previously served in positions of increasing responsibility as a management consultant, project leader and ultimately as principal in the healthcare practice of The Boston Consulting Group, where he advised companies in the biotechnology, pharmaceutical and life science industries on business strategy, operational performance and mergers and acquisitions. Prior to joining BCG, he worked in research positions at Symyx Technologies and MIT Lincoln Laboratory. Dr. Bilinsky received his B.S. degree in physics from the Moscow Institute of Physics and Technology and his Ph.D. degree in physics from the Massachusetts Institute of Technology.

Research Interest

Pharma, Clinical research, Pharmaceutical sciences